Jazz Pharmaceuticals plc (JAZZ) company profile
Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –
About Jazz Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Jazz Pharmaceuticals plc is a biopharmaceutical company that discovers, develops, and commercializes therapeutic medicines for patients facing rare diseases, particularly conditions with limited treatment options. The company focuses its portfolio across therapeutic areas addressing rare sleep disorders, rare epilepsies, and rare oncology. Key commercial products include Xywav and Xyrem for sleep disorders such as narcolepsy and idiopathic hypersomnia; Epidiolex for severe childhood-onset seizure syndromes including Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex; and oncology therapies such as Ziihera, Modeyso, Zepzelca, and Rylaze for diverse cancers. Its customers comprise adult and pediatric patients diagnosed with these targeted conditions.
The company maintains an international commercial footprint, marketing approved therapies to patients across multiple global regions. Key international territories and markets explicitly served include the United States, Canada, the European Union, Great Britain, Switzerland, Australia, and Israel, with its rare epilepsy medicine launched and reimbursed in more than 40 countries. In the United States, its primary sleep disorder medicines are distributed directly to individuals through an exclusive central pharmacy. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Jazz Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Jazz Pharmaceuticals plc
- Founded
- 2003
- Headquarters
- Dublin, Ireland
- Address
- Fifth Floor, Waterloo Exchange, Waterloo Road D04 E5W7
- Phone
- 353-1-634-7800
- Website
- www.jazzpharma.com
- Employees
- 2,890, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L2
- Fiscal year ends
- December 31
- Auditor
- KPMG, Dublin, Ireland
Stock & identifiers
- Ticker
- JAZZ
- Exchange
- Nasdaq
- IPO date
- Jun 1, 2007
- Shares outstanding
- 65M, Jul 27, 2026
- Public float
- $6.25B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1232524
- CUSIP
- G50871105
- FIGI
- BBG000G9CGL0
- Share class FIGI
- BBG001SNW8K1
- LEI
- 635400GAUMJCLEZRRV50
- EIN
- 98-1032470
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Renee D. Gala | President & CEO, Director | 140,394 |
| Patricia Carr | SVP, Chief Accounting Officer | 6,512 |
| Neena M. Patil | EVP & Chief Legal Officer | 47,671 |
| Mary Elizabeth Henderson | SVP, Technical Operations | 23,815 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 112,107 |
| Samantha Pearce | EVP, Chief Commercial Officer | 47,131 |
| Philip L. Johnson | EVP & Chief Financial Officer | 56,431 |
| Bruce C. Cozadd | Director | 357,567 |
| Patrick Kennedy | Director | 8,292 |
| Laura Hamill | Director | 8,524 |
| Norbert G. Riedel | Director | 17,553 |
| Heather Ann McSharry | Director | 18,199 |
| Mark Douglas Smith | Director | 9,579 |
| Ted W. Love | Director | 2,389 |
| Rick E. Winningham | Director | 9,480 |
| Patrick G. Enright | Director | 21,278 |
| Jennifer E. Cook | Director | 10,736 |
| Seamus Mulligan | Director | 1,286,254 |
| Kenneth W. O'Keefe | Director | 30,256 |
| Anne ORiordan | Director | 16,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Bruce C.Cozadd | $18.83M | $24.13M | $7.13M | $103 | $125 |
| FY2025 Renee D.Gala | $19.15M | $29.78M | $7.13M | $103 | $125 |
| FY2024 | $15.53M | $17.26M | $4.70M | $75 | $93 |
| FY2023 | $15.34M | -$2.50M | $4.23M | $75 | $94 |
| FY2022 | $17.33M | $26.32M | $5.04M | $97 | $90 |
| FY2021 | $15.68M | $4.92M | $4.54M | $77 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Renee D. Gala President, CEO and Director | $1.00M | – | $16.14M | – | $1.98M | $29.86K | $19.15M | +189% |
| Philip L. Johnson Executive Vice President and CFO | $741.35K | – | $6.05M | – | $730.00K | $26.22K | $7.54M | +44% |
| Bruce C. Cozadd Chairperson and former CEO | $884.79K | $971.09K | $4.86M | $12.04M | – | $82.44K | $18.83M | +21% |
| Robert Iannone, M.D., M.S.C.E Executive Vice President, Global Head of R&D | $793.08K | – | $6.95M | – | $840.00K | $24.80K | $8.66M | +52% |
| Neena M. Patil Executive Vice President and Chief Legal Officer | $715.48K | – | $4.84M | – | $720.00K | $19.96K | $6.30M | +46% |
| Samantha Pearce Executive Vice President, Chief Commercial Officer | $695.67K | – | $4.66M | – | $690.00K | $31.44K | $6.08M | +36% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 1, 2007
- Securities offered
- 6,000,000
- Exchange
- Nasdaq
- First trading day
- Jun 1, 2007
- First-day close
- $17.73
- Lock-up ends (est.)
- Nov 28, 2007
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Jazz employed approximately 2,890 people worldwide, with approximately 53% in the U.S.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?